Papers/PMID:27589059
MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study.
Multiple sclerosis (Houndmills, Basingstoke, England)2016The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
biotin — decreases expanded Disability Status Scale (EDSS)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“At month 12, the mean (±standard deviation (SD)) EDSS decreased from baseline in the MD1003 arm (−0.03 ± 0.50) but increased at the expected rate in the placebo arm (+0.13 ± 0.33, p = 0.01; Figure 3).”
Quoted verbatim from MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study.. - Study
- RCT
- Participants
- 154
- Duration
- 12 months
- Dose
- 100 mg biotin orally three times daily (300 mg/day)
- Population
- Adults aged 18-75 with primary or secondary progressive multiple sclerosis, baseline EDSS 4.5-7 and disease worsening in the previous 2 years; month 12 of the double-blind phase; all patients on stable concomitant therapy allowed
MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study.2016PMID:27589059Industry fundedPermalink